Federal contract award
75N94019F00126
TASK ORDER 2: STATUS DETERMINATION AND PRIORITIZATION OF PIPELINE PRODUCTS UNDERGOING CLINICAL TRIALS FOR MALE AND FEMALE CONTRACEPTION
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NICHD |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 75N94019D00004 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $2.5M |
| Current contract value | $2.5M |
| Potential contract value / ceiling | $2.5M |
| Start date | Sep 24, 2019 |
| Current end date | Dec 31, 2028 |
| Potential end date | Dec 31, 2028 |
| Latest award activity | Sep 10, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 10, 2026 | P00004 | $898.2K | NICHD: R&D: STATUS DETERMINATION AND PRIORITIZATION OF PIPELINE PRODUCTS UNDERGOING CLINICAL TRIALS FOR MALE AND FEMALE CONTRACEPTION: NON-SEVERABLE |
| May 21, 2025 | P00003 | $0 | NICHD: R&D: STATUS DETERMINATION AND PRIORITIZATION OF PIPELINE PRODUCTS UNDERGOING CLINICAL TRIALS FOR MALE AND FEMALE CONTRACEPTION: NON-SEVERABLE |
| Mar 28, 2024 | P00002 | $249.2K | TASK ORDER 2: STATUS DETERMINATION AND PRIORITIZATION OF PIPELINE PRODUCTS UNDERGOING CLINICAL TRIALS FOR MALE AND FEMALE CONTRACEPTION |
| Sep 22, 2023 | P00001 | $50.0K | TASK ORDER 2: STATUS DETERMINATION AND PRIORITIZATION OF PIPELINE PRODUCTS UNDERGOING CLINICAL TRIALS FOR MALE AND FEMALE CONTRACEPTION |
| Sep 24, 2019 | 0 | $1.3M | TASK ORDER 2: STATUS DETERMINATION AND PRIORITIZATION OF PIPELINE PRODUCTS UNDERGOING CLINICAL TRIALS FOR MALE AND FEMALE CONTRACEPTION |
Estimated positioning window
Dec 31, 2027 – Jun 30, 2028
65/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 65/100. Available recorded signals: 60 points.
- Contract end 2028-12-31 (798 days from calculation)
- +15 points
- 132 historical awards in this buyer and category group
- +15 points
- 5 recorded award transactions
- +10 points
- Latest award action: 2026-09-10
- +5 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.